

February 10, 2025

The Manager –Listing
BSE Limited

Corporate Relationship Dept.,
1st Floor, New Trading Ring
Rotunda Building, P J Towers,
Dalal Street, Fort, Mumbai 400001

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir/Ma'am,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company has received a warning letter from National Stock Exchange of India Limited ('NSE') on February 7, 2025.

The information pertaining to the said letter in terms of Regulation 30 of SEBI Listing Regulations, in the prescribed format, is given as **Annexure - 1**.

Further, the said letter received from NSE is enclosed as **Annexure – 2**.

This is to bring to your attention that the Company acknowledges receipt of a letter via email dated February 7, 2025 at 17:02. However, the contents of the said email and letter were accessed and reviewed on February 10, 2025.

Kindly take the above information on record.

Thanking You

For AstraZeneca Pharma India Limited

Manasa. R
Company Secretary

Annexure - 1

Sl. No.	Particulars	Response
1.	Name of the Authority	National Stock Exchange of India Limited
2.	Nature and details of the action(s) taken, initiated or order(s) passed	Warning letter
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	February 7, 2025
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Quorum for the Audit Committee meeting held on May 27, 2024 not met under Regulation 18(2)(b) of the SEBI Listing Regulations
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	None

National Stock Exchange Of India Limited

Ref: NSE/LIST/COMP/ASTRAZEN/01/2024-2025

Date: February 07, 2025

To,
The Company Secretary,
AstraZeneca Pharma India Limited,
Block N1, 12 Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore, Karnataka- 560045

Subject: Warning letter

Dear Sir/Madam,

This is in reference to the Corporate Governance Report submitted by AstraZeneca Pharma India Limited ('the Company') for quarter ended June 2024. Further, referring to Regulation 18(2)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI LODR') which states that:

18(2)(b) The quorum for audit committee meeting shall either be two members or one third of the members of the audit committee, whichever is greater, with at least two independent directors.

It was observed that the Company is in non-compliance with the provisions of Regulation 18(2)(b) of LODR, as only one independent director attended the audit committee meeting held on May 27, 2024.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be careful in future, exercise due caution and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the Exchange circulars/guidance/communications. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this warning letter on the Stock Exchange(s) where it is listed. Additionally, the Company is advised to place before their Board of Directors this warning letter and the corrective measures taken by the Company to avoid such lapses.

Yours faithfully,
for **National Stock Exchange of India Limited**

Raksha Jain
Senior Manager – Listing Compliance